MiMedx Group, Inc
Here’s whether MiMedx Group, Inc (MDXG) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 44 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-8.10% over 10 days); weak 1-year return of -41.8%; 3-month momentum negative (-27.7%); rising volume on a downtrend (distribution, 1.27x avg). Currently 53.9% off its 52-week high. Score: -5/7.
MDXG is trading below its 200-day MA ($6.04) — a key warning sign the longer-term trend is under pressure. An RSI of 44.0 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -41.8% compares to +27.9% for SPY (trailed the market by 69.7%). The current 53.9% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.